JNJJohnson & Johnson
Is the business good?
The checks split: nothing decisive, though margins widening.
Mixed fundamental signals. Nine pass/fail tests of year-over-year health from the filings.
Positive operating leverage, operating profit is growing faster than sales, so margins widen as the business scales.
Margin-driven, fat margins on slower asset turns. ROE 26% = margin × turnover × leverage.
Unless marked, from derived.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.
How good a business is JNJ?
Johnson & Johnson keeps 16% of every revenue dollar as profit after everything, against 13% for the median Drug Manufacturers - General name.
Net margin · Drug Manufacturers - General median 13% · 12 months to Q3 2026
- Share count, year on year
- +0.82%
Share count, year on year · flat: no meaningful dilution
- R&D as % of revenue
- 16%
R&D as % of revenue
- Gross margin
- 68%
Gross margin
Details›
- Gross margin12 months to Q3 2026
- 68%
- Net margin12 months to Q3 2026
- 16%
- Free cash flow margin
- 21%
- R&D as % of revenue
- 16%
- Revenue, trailing twelve months
- $99.3B
- Free cash flow, trailing twelve months
- $20.6B
- Net income, trailing twelve months
- $16.1B
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
Drug Manufacturers, General
The closest names by size in the same industry